Abstract:OBJECTIVE:To build the multiple drug resistant human laryngeal cancer cell line and investigate its characteristics.METHOD:Human laryngeal cancer cells were exposed in stepwise escalating concentration of Taxol until the resistant cell line was developed. The IC50 and the resistance folds of multidrug resistance were detected by an ATP assay. The differences of cell cycle distribution, apoptosis, and Rhodamine accumulation between Hep-2 and Hep-2T cells were studied through flow cytometry. The MDR1 and MRP1 gene were detected through realtime quantitative RT-PCR, and the corresponding protein was detected through western-blotting.RESULT:A multidrug resistance cell line-Hep-2T induced by Taxol was effectively developed, whose drug resistance was 104 times that of Hep-2 cells. Doxorubicin, Gemcitabine, 5-Fu, Cisplatin all increased the drug resistance by 46.78, 1.95, 2.50, 1.05 folds. The cell cycle distribution altered. The apoptosis of Hep-2 cells was quite greater than that of Hep-2T cells (45.32% vs 4.26%, P < 0.01, flow cytometry), (54.47 +/- 48.95 vs 9.84 +/- 12.53 P < 0.01, hoechst staining) after Hep-2 and Hep-2T exposed to Taxol at IC50 to Hep-2. The copy ratio of MDR1/GAPDH mRNA of Hep-2T was 64.2 +/- 36.7 times that of Hep-2 (P < 0.05), while MRP1/GAPDH of Hep-2T was only 1.20 +/- 0.09 folds more than that of Hep-2 (P < 0.05). The proteins of MDR1/P-gp were greatly over expressed in Hep-2T cells compared with Hep-2 cells (P < 0.01) whose was in the same trend (P < 0.05), while the elevated expression of MRP1 was lower than that of MDR1/P-gp.CONCLUSION:When considering the possible methods to reverse MDR of SCCHN, more emphasis should be laid on MDR1/P-gp, and when combining this with chemotherapy the non-P-gp substrate chemotherapeutic agents should be considered. At the same time, more attention should be paid to the changes of cell cycle distribution during the drug selection.

Characteristics of Doxorubicin-Selected Multidrug-Resistant Human Leukemia HL-60 Cells with Tolerance to Arsenic Trioxide and Contribution of Leukemia Stem Cells.

Differential Expression and Response to Arsenic Stress of MRPs and ASAN1 Determine Sensitivity of Classical Multidrug-Resistant Leukemia Cells to Arsenic Trioxide

Multidrug Resistance Protein 1 ( ABCC1 ) Confers Resistance to Arsenic Compounds in Human Myeloid Leukemic HL-60 Cells

DEVELOPMENT OF A K562 MULTIDRUG-RESISTANT CELL LINE AND STUDY ON PROTEINS WITH ALTERED EXPRESSION

In Doxorubicin-Adapted Hodgkin Lymphoma Cells, Acquiring Multidrug Resistance and Improved Immunosuppressive Abilities, Doxorubicin Activity Was Enhanced by Chloroquine and GW4869

[The Relationship Between Multi-Drug Resistance and Proportion of Leukemia Stem Cells and Expression of Drug Transporters in Drug-Resistant Leukemia K562/ADM Cells].

Disulfiram/copper Complex Activated JNK/c-jun Pathway and Sensitized Cytotoxicity of Doxorubicin in Doxorubicin Resistant Leukemia HL60 Cells.

Relationship Between Expression of Cell Regulatory Factor SKP2 and Drug Resistance of HL-60/A Cells

A Novel Resveratrol-Arsenic Trioxide Combination Treatment Synergistically Induces Apoptosis of Adriamycin-Selected Drug-Resistant Leukemia K562 Cells.

Chemoresistant Leukemia-Initiating Cell Expansion is Inhibited by Targeting Oncogenic Self-Renewal

[Transfection of HL-60 Cells with CYP3A5 Gene Induces Drug-Resistant Phenotype].

The Overexpression of Multidrug Resistance-Associated Proteins and Gankyrin Contribute to Arsenic Trioxide Resistance in Liver and Gastric Cancer Cells

[Multidrug Resistance Mechanisms in Cell Line HL-60/VCR].

Overcoming Wnt–β-catenin Dependent Anticancer Therapy Resistance in Leukaemia Stem Cells

Multi-Drug-Resistant Cells Enriched From Chronic Myeloid Leukemia Cells By Doxorubicin Possess Tumor-Initiating-Cell Properties

Arsenic Trioxide Inhibits P-Glycoprotein Expression In Multidrug-Resistant Human Leukemia Cells That Overexpress The Mdr1 Gene

SLC25A40 Facilitates Anticancer Drug Resistance in Human Leukemia K562 Cells

The Building of Multiple Drug Resistant Human Laryngeal Cancer Cell Line and Its Characteristics

Disulfiram/Cu activated MAPK pathways and reverse drug resistance of adriamycin resistant leukemia cells

Prevention of Adriamycin-Induced Drug-Resistance of Leukemia Cells by Α-Tocopheryl Succinate and Arsenic Trioxide

Arsenic Trioxide Reduces Drug Resistance to Adriamycin in Leukemic K562/A02 Cells Via Multiple Mechanisms.